Existing investor Syngenta Ventures was among the participants as the agricultural bioprocessing platform developer raised capital that will support commercialisation.
US-based bioprocessing technology developer GreenLight Biosciences closed an $18m series D round yesterday featuring Syngenta Ventures, the strategic investment arm of agribusiness Syngenta.
Private equity firm Fall Line Capital led the round, which was also backed by S2G Ventures, Lewis and Clark Ventures, Macro Capital Investments and existing investors that included Kodiak Venture Partners and MLSCF, the Malaysian Life Sciences Capital Fund.
GreenLight has created a cell-free bioprocessing platform it claims can produce high-fidelity RNA sequences far more affordably than…
